2017

1. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

   Annals of Oncology, Vol. 28, Núm. 2, pp. 313-320

2. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

   The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700